Patients with CKD have a 56% higher prevalence of severe mental health disorders such as schizophrenia, bipolar disorder, or ...
Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney disease — ischemic benefits not observed in trials of selective SGLT2 inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback